India Considers Bulk Buys Of Costly MNC Devices, Drugs
This article was originally published in PharmAsia News
Indian authorities are considering buying certain medical devices and drugs in volume to ensure they are more affordable to Indians who need them. Under the plan, multinational companies would be barred from having direct access to patients if they have a monopoly over expensive products. Government officials believe the companies also would benefit because they would have a massive contract for their products without the high cost of promoting them. Some drug makers already sell pharmaceuticals in India at prices lower than those they charge in developed countries. (Click here for more
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.